CLEC12A and acute myeloid leukemia: Moreover, CLL1 is present on a small population of chemotherapy-resistant leukemic stem cells hypothesized to be responsible for relapse [14,15], making it an ideal target antigen for the treatment of AML patients with CAR-T-cells [12,13,15].